Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-828 has been nominated as a candidate drug (CD) for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.
AML arises from cells in the bone marrow that are supposed to develop into normal white blood cells but become cancerous instead. These malignant cells build up in the bone marrow, preventing the development of normal blood cells. Many patients are unable to tolerate current therapies. The preclinical data indicate that MIV-828 may become a better tolerated and more effective medicine for patients with AML and other hematological cancers.
“Patients with AML are urgently in need of more effective and better tolerated drugs, and I strongly believe that MIV-828 has the potential to become a future cornerstone in the therapy of AML and related cancers,” said Dr Uli Hacksell, Medivir’s Chief Executive Officer. “I would also like to express my appreciation to Medivir’s outstanding research team for delivering yet another high quality candidate drug”.